Skyrizi vs Tremfya (Risankizumab Vs Guselkumab) – Comparison

Skyrizi vs Tremfya (Risankizumab Vs Guselkumab) is a comparison of the two monoclonal antibodies which selectively target and block Interleukin-23. IL-23 is an inflammatory cytokine that activates CD4 + T-helper (Th17) cell pathway to activate the inflammation cascade that is responsible for psoriatic plaque formation.  Both of these drugs are indicated in the treatment of … Read more